Comparative Pharmacology
Head-to-head clinical analysis: DIFLUCAN versus MONISTAT 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFLUCAN versus MONISTAT 5.
DIFLUCAN vs MONISTAT 5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diflucan (fluconazole) is a triazole antifungal agent that inhibits fungal cytochrome P450 14-alpha-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability and inhibition of fungal growth.
Miconazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Oral or IV: 200-400 mg loading dose, then 100-200 mg once daily. Dose and duration depend on indication.
Miconazole nitrate 100 mg vaginal suppository inserted once daily at bedtime for 3 days; or 200 mg vaginal suppository once daily at bedtime for 3 days; or 1200 mg vaginal suppository as a single dose.
None Documented
None Documented
30 hours (range 20-50 hours); prolonged in renal impairment (up to 98 hours in CrCl <20 mL/min)
Terminal half-life approximately 24 hours; supports once-daily dosing.
Renal: 80% unchanged; fecal/biliary: 11% as metabolites
Primarily fecal (90%) as unchanged drug; renal excretion minimal (<1%).
Category C
Category C
Antifungal
Antifungal